Patents by Inventor Eugene Hickey

Eugene Hickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20240376095
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: January 8, 2024
    Publication date: November 14, 2024
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • OPTIMIZING OPERATOR CONFIGURATION IN CONTAINERIZED ENVIRONMENTS
    Publication number: 20240248695
    Abstract: Computer technology for optimizing operator configuration for deployment of an application in a container orchestration cluster. The computer technology includes machine logic for performing the following operations: collecting historical data for deployment data including operator configurations, cluster configurations, and behavior data. The method models the deployment data using embedded matrix models; and applies collaborative filtering to process the modeled data to map user requirements for a target deployment to deployment configurations of previous successful deployments; to output one or more predicted deployment configurations as a reference for the target deployment.
    Type: Application
    Filed: March 3, 2023
    Publication date: July 25, 2024
    Inventors: MARTIN HICKEY, Eugene Michael Maximilien
  • INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7)
    Publication number: 20240174632
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 30, 2024
    Applicant: Morphic Therapeutic, Inc.
    Inventors: Matthew G. BURSAVICH, Dan CUI, James E. DOWLING, Kristopher N. HAHN, Bryce A. HARRISON, Fu-Yang LIN, Blaise S. LIPPA, Bruce N. ROGERS, Dawn M. TROAST, Cheng ZHONG, Kyle D. KONZE, Aleksey I. GERASYUTO, Byungchan KIM, Salma RAFI, Tyler DAY, Eugene HICKEY, Evelyne HOUANG, Robert ZAHLER
  • Inhibiting (?-v)(?-6) integrin
    Patent number: 11739087
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: August 29, 2023
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20230242524
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 17, 2022
    Publication date: August 3, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20230219949
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 19, 2022
    Publication date: July 13, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew M. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Tyler Day, Byungchan Kim, Kyle D. Konze
  • INHIBITORS OF AV ß6 INTEGRIN
    Publication number: 20230219947
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: October 17, 2022
    Publication date: July 13, 2023
    Inventors: Bryce A. Harrison, James E. Dowling, Aleksey I. Gerasyuto, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Inhibiting human integrin (alpha-4) (beta-7)
    Patent number: 11370773
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: June 28, 2022
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20220073511
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 10, 2022
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Inhibiting human integrin (?-4) (?-7)
    Patent number: 11104661
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: August 31, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200385384
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 10, 2020
    Inventors: Bryce A. Harrison, James J. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200354359
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200071322
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
    Patent number: 7405225
    Abstract: Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: July 29, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Zhidong Chen, Jonathan Emeigh, Roman Wolfgang Fleck, Ming-Hong Hao, Eugene Hickey, Weimin Liu, Daniel Richard Marshall, Tina Morwick, Peter Nemoto, Ronald John Sorcek, Sanxing Sun, Jiang-Ping Wu
  • Compounds which Modulate the CB2 Receptor
    Publication number: 20080081822
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Application
    Filed: September 13, 2007
    Publication date: April 3, 2008
    Inventors: Angela Berry, Pier Cirillo, Eugene Hickey, Doris Riether, David Thomson, Renee Zindell, Nigel Blumire, Chandana Chowdhury, Monika Ermann, James Jenkins, Innocent Mushi, Christopher Palmer, Malcolm Taylor
  • Compounds Which Modulate The CB2 Receptor
    Publication number: 20080039464
    Abstract: Compound of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Application
    Filed: July 23, 2007
    Publication date: February 14, 2008
    Inventors: Angela BERRY, Pier CIRILLO, Eugene HICKEY, Doris RIETHER, David Thomson, Monika ERMANN, James JENKINS, Innocent MUSHI, Malcolm TAYLOR, Chandana CHOWDHURY, Christopher PALMER, Nigel BLUMIRE
  • Substituted Tricyclic Heterocycles and their Uses
    Publication number: 20080008720
    Abstract: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.
    Type: Application
    Filed: August 9, 2007
    Publication date: January 10, 2008
    Inventors: Charles Cywin, Roman Fleck, Eugene Hickey, Weimin Liu, Tina Morwick, John Proudfoot, Denice Spero
  • Compounds Which Modulate The CB2 Receptor
    Publication number: 20070191340
    Abstract: Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula wherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.
    Type: Application
    Filed: December 8, 2006
    Publication date: August 16, 2007
    Inventors: Renee Zindell, Doris Riether, David Thomson, Eugene Hickey, Innocent Mushi, Monika Ermann
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Publication number: 20060025433
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 6, 2005
    Publication date: February 2, 2006
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Antonio Barbosa, Steven Brunette, Eugene Hickey, Jin Kim, Michael Lawlor, Rene Lemieux, Bryan McKibben, Matt Tschantz, Hui Yu
  • Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
    Publication number: 20050288285
    Abstract: Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Application
    Filed: August 18, 2005
    Publication date: December 29, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles Cywin, Zhidong Chen, Roman Fleck, Ming-Hong Hao, Eugene Hickey, Weimin Liu, Daniel Marshall, Peter Nemoto, Ronald Sorcek, Sanxing Sun, Jiang-Ping Wu, Tina Morwick, Jonathan Emeigh